<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334502</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N1085</org_study_id>
    <secondary_id>NCCTG-N1085</secondary_id>
    <secondary_id>CDR0000698584</secondary_id>
    <secondary_id>NCI-2011-02643</secondary_id>
    <nct_id>NCT01334502</nct_id>
  </id_info>
  <brief_title>Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer cells in&#xD;
      different ways. Some block the ability of cancer cells to grow and spread. Others find cancer&#xD;
      cells and help kill them or carry cancer-killing substances to them. Drugs used in&#xD;
      chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and&#xD;
      prednisone, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or stopping them from dividing. Giving everolimus together with rituximab,&#xD;
      cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone may kill&#xD;
      more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and the best dose of everolimus when&#xD;
      given together with rituximab and combination chemotherapy in treating patients with newly&#xD;
      diagnosed untreated diffuse large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish the maximum-tolerated dose (MTD) of everolimus in combination with R-CHOP&#xD;
           (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and&#xD;
           prednisone) chemotherapy.&#xD;
&#xD;
        -  To assess the feasibility of everolimus in combination with standard R-CHOP chemotherapy&#xD;
           in patients with newly diagnosed diffuse large B-cell lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To describe the toxicities associated with everolimus in combination with R-CHOP&#xD;
           chemotherapy.&#xD;
&#xD;
        -  To further describe the toxicities associated with everolimus in combination with R-CHOP&#xD;
           chemotherapy.&#xD;
&#xD;
        -  To assess the rate of event-free survival (EFS) at 12 months for diffuse large B-cell&#xD;
           lymphoma patients treated with everolimus in combination with R-CHOP chemotherapy.&#xD;
&#xD;
        -  To evaluate overall response rate, complete response rate, duration of response, EFS,&#xD;
           overall survival, and progression-free survival for patients treated with everolimus in&#xD;
           combination with R-CHOP chemotherapy.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  To profile gene expression using immunohistochemistry and categorize patients as&#xD;
           germinal-center B-cell-like (GBC) vs activated B-cell-like (ABC) vs unclassified&#xD;
           lymphoma subtype. (exploratory)&#xD;
&#xD;
        -  To determine whether previously identified predictive markers in large cell lymphoma&#xD;
           remain valid with the addition of everolimus to R-CHOP chemotherapy. (exploratory)&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of everolimus followed by a feasability&#xD;
      expanded-cohort study.&#xD;
&#xD;
      Patients receive everolimus orally (PO) once daily (QD) on days 1-10 or 1-14; rituximab IV,&#xD;
      cyclophosphamide IV, doxorubicin hydrochloride IV over 15-60 minutes, and vincristine sulfate&#xD;
      IV on day 1; and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Tumor biopsies are collected for laboratory studies and patients may undergo blood and needle&#xD;
      biopsy sample collection for correlative studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3-6 months for up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of everolimus in combination with R-CHOP</measure>
    <time_frame>Up to 15 months post registration to Phase I portion of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events profile</measure>
    <time_frame>Up to 15 months post registration to Phase I portion of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>Up to 15 months post registration to Phase I portion of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who have a significant toxicity</measure>
    <time_frame>Up to 2.5 years post registration to Feasibility portion of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of EFS</measure>
    <time_frame>Up to 5 years post treatment of the feasibility portion of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate, CR rate, overall survival, PFS, and duration of response</measure>
    <time_frame>Up to 5 years post treatment of the feasibility portion of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>everolimus and RCHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>PO</description>
    <arm_group_label>everolimus and RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>IV</description>
    <arm_group_label>everolimus and RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>IV</description>
    <arm_group_label>everolimus and RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>PO</description>
    <arm_group_label>everolimus and RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>PO</description>
    <arm_group_label>everolimus and RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>IV</description>
    <arm_group_label>everolimus and RCHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Untreated, histological diagnosis of CD20-positive diffuse large B-cell lymphoma&#xD;
&#xD;
          -  Stage II-IV (Ann Arbor Staging)&#xD;
&#xD;
          -  Measurable or assessable disease defined as at least one of the following:&#xD;
&#xD;
               -  A lymph node or tumor mass that is â‰¥ 2.0 cm in at least one dimension by CT&#xD;
                  portion of PET/CT scan, CT scan, or MRI&#xD;
&#xD;
               -  Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral&#xD;
                  blood, liver, lungs, or bowel by lymphoma without a discrete mass would&#xD;
                  constitute assessable, but not measurable, disease&#xD;
&#xD;
          -  Diagnostic tissue slides and paraffin-embedded block must be available&#xD;
&#xD;
          -  No CNS lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) â‰¥ 1,500/mmÂ³&#xD;
&#xD;
          -  Peripheral platelet count â‰¥ 100,000/mmÂ³&#xD;
&#xD;
          -  Hemoglobin (HgB) &gt; 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin â‰¤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  For total bilirubin &gt; 1.5 times ULN, the direct bilirubin must be normal&#xD;
&#xD;
          -  Alkaline phosphatase â‰¤ 3 times ULN (â‰¤ 5 times ULN if evidence of direct liver&#xD;
             involvement by lymphoma)&#xD;
&#xD;
          -  AST â‰¤ 3 times ULN (â‰¤ 5 times ULN if evidence of direct liver involvement by lymphoma)&#xD;
&#xD;
          -  Creatinine â‰¤ ULN&#xD;
&#xD;
          -  Negative serum or urine pregnancy test&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Men or women of childbearing potential must be willing to employ adequate&#xD;
             contraception throughout the study and for12 months after the last dose of study drug&#xD;
&#xD;
          -  Willing to return to the National Central Cancer Treatment Group (NCCTG) enrolling&#xD;
             institution for follow-up&#xD;
&#xD;
          -  Willing to provide archival tissue from the primary diagnosis (original lymphoma lymph&#xD;
             node tissue biopsy)&#xD;
&#xD;
          -  Willing to abstain from eating grapefruit or drinking grapefruit juice for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Diabetic patients who are taking insulin or oral anti-diabetic therapy must have HbA1c&#xD;
             â‰¤ 8%, or a fasting serum glucose â‰¤ 110% ULN&#xD;
&#xD;
          -  HIV-positive patients must have CD4 count â‰¥ 400/mmÂ³&#xD;
&#xD;
          -  No co-morbid systemic illnesses or other severe concurrent disease that, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into this&#xD;
             study or interfere significantly with the proper assessment of safety and toxicity of&#xD;
             the prescribed regimens&#xD;
&#xD;
          -  No immunocompromised patients (other than that related to the use of corticosteroids)&#xD;
             including patients known to be HIV positive with a CD4 count of &lt; 400/mmÂ³&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Severely impaired lung function&#xD;
&#xD;
               -  Uncontrolled diabetes as defined by fasting serum glucose &gt; 1.5 times ULN&#xD;
&#xD;
                    -  Optimal glycemic control should be achieved before starting trial therapy&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
               -  Liver disease such as cirrhosis or severe hepatic impairment&#xD;
&#xD;
               -  Chronic active hepatitis&#xD;
&#xD;
               -  Chronic persistent hepatitis or history of hepatitis B or C&#xD;
&#xD;
          -  No other active malignancy except non-melanotic skin cancer or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
               -  If there is a history of prior malignancy, patients must not be receiving other&#xD;
                  specific treatment (other than hormonal therapy) for their cancer&#xD;
&#xD;
          -  No positive hepatitis B antigen (HBsAg) or hepatitis C serology (HCV) tests meeting&#xD;
             the following criteria:&#xD;
&#xD;
               -  Hepatitis B surface antigen (HbsAg) and antibody to hepatitis B core (anti-HBc)&#xD;
                  or hepatitis C antibody&#xD;
&#xD;
               -  All patients must be screened prior to registration&#xD;
&#xD;
               -  Patients who have evidence of chronic or acute infection with either hepatitis B&#xD;
                  or C may not be treated on this protocol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not receiving any other investigational agent that would be considered as a treatment&#xD;
             for the primary neoplasm&#xD;
&#xD;
          -  No planned immunization with attenuated live vaccines â‰¤ 7 days prior to registration&#xD;
             or during study period&#xD;
&#xD;
               -  Close contact with those who have received attenuated live vaccines should be&#xD;
                  avoided during treatment with everolimus&#xD;
&#xD;
               -  Examples of live vaccines include intranasal influenza, measles, mumps, rubella,&#xD;
                  oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines&#xD;
&#xD;
          -  Not currently on enzyme-inducing anti-convulsants or other strong inducers of CYP3A4&#xD;
             (efavirenz, nevirapine, barbiturates, carbamazepine, modafinil, phenobarbital,&#xD;
             phenytoin, rifabutin, rifampin, pioglitazone, or St. John wort) or strong inhibitors&#xD;
             of CYP3A4 (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole,&#xD;
             voriconazole, ketoconazole, nefazodone, saquinavir, or telithromycin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Johnston, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

